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1  | INTRODUC TION
Peyronie's Disease is considered a wound-healing disorder causing 
formation of a collagen plague in the tunica albuginea of the penis 
subsequently leading to deformities including penile shortening, ab-
normal penile curvature and possibly subsequent erectile dysfunc-
tion (Mulhall, Schiff, & Guhring, 2006; Smith, Walsh, Conti, Turek, & 
Lue, 2008). Abnormal penile curvature is highly prevalent in patients 
diagnosed with Peyronie's Disease, and depending on the severity 
of the curvature, sexual intercourse is often difficult and unpleasant 
(Gelbard, Hellstrom, et al., 2013; Smith et al., 2008). Furthermore, 
the curvature itself and dissatisfactory intercourse may have a major 
psychological impact on patients and treatment is vital to increase 
patient's sexual health and quality of life (Nelson et al., 2008; Smith 
et al., 2008).
Historically, the only effective treatment for penile curvature 
caused by Peyronie's Disease has been surgery, which today re-
mains the gold standard (Yafi et al., 2018). In 2013, the US Food and 
Drug Administration approved the use of Collagenase Clostridium 
Histolyticum injections (CCHi) given intralesionally. The approval 
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The aim of this study was to evaluate patient-reported outcomes of Collagenase 
Clostridium Histolyticum (CCHi) for Peyronie's Disease. Patients treated with 2–4 
cycles of CCHi between 01/2016 and 08/2018 were asked to fill out the “bother 
domain” of the Peyronie's Disease Questionnaire (PDQ) at scheduled appointments 
for injections. CCHi cycles involved two injections (0.58 mg) separated by 48–72 hr. 
During the study, 34 patients were treated, seven patients were excluded due to 
incomplete baseline values. Mean (standard deviation) PDQ bother domain baseline 
score	was	11.1	(2.6).	ANOVA	demonstrated	statistically	significant	effects	of	injec-
tions (p < .001) with a decrease in PDQ bother domain scores 6 weeks after the 
1st cycle (9.9 [3.3], p = .013), 6 weeks after the 2nd cycle (8.2 [4.0], p = .009) and 
6 weeks after the 3rd cycle (6.5 [3.6], p < .001). After 2–4 cycles of CCHi treatment, 
patients reported changes in penile curvature as “Worse” (0), “No Change” (2), “Little 
decrease” (10), Decrease (10) and “Significant decrease” (4). After completion of CCHi 
treatment, 82% of patients still reported that vaginal intercourse was difficult or im-
possible. Patients with Peyronie's Disease undergoing CCHi treatment reported sta-
tistically significant decreases in PDQ bother domain scores. However, most patients 
still report difficulty with intercourse after treatment.
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was based on the Investigation for Maximal Peyronie's Reduction 
Efficacy and Safety Studies (IMPRESS) trials (Gelbard, Goldstein, 
et al., 2013) demonstrating that CCHi significantly reduces penile 
curvature. IMPRESS I and II included 832 patients, and after four 
cycles of CCHi, penile curvatures were reduced by a mean of 34% 
compared with a mean of 18.2% in the placebo group (p < .0001). 
Following the approval, more studies were conducted based on 
the IMPRESS protocol showing both positive and inconclusive re-
sults	of	CCHi	 (Wymer,	Ziegelmann,	Savage,	Kohler,	&	Trost,	2018;	
Yafi et al., 2018; Yang & Bennett, 2016). The main outcome mea-
sure in most of these studies is penile curvature measured as the 
angle between the proximal shaft and the distal part of the penis. 
Although penile curvature is considered an objective treatment pa-
rameter for evaluating CCHi treatment, curvature reduction does 
not always align with patient satisfaction after treatment (Tsambarlis 
& Levine, 2019). Other parameters, for example pain during sexual 
intercourse, can be more important to patients. These parameters 
are assessed in the Peyronie's Disease questionnaire (PDQ) bother 
domain which consists of four scored items and two yes/no ques-
tions including questions regarding vaginal intercourse and the pa-
tient's perception of his penis. The PDQ bother score ranges from 0 
to 16, and a higher score indicates greater bother severity. The aim 
of this prospective non-randomised clinical study was to evaluate 
patient-reported outcomes (PROs) of CCHi for Peyronie's Disease in 
a post-marketing real-life clinical setting.
2  | MATERIAL AND METHODS
2.1 | Patients
Institutional review board approval was obtained to review 
charts	of	all	men	between	January	2016	and	August	2018	at	the	
University of Michigan, Department of Urology, who underwent 
treatment with CCHi. Patients with dorsal, dorsolateral or lateral 
penile curvatures between 30 and 90 degrees eligible for CCHi 
treatment were asked to complete the PDQ prior to each series of 
injections. According to health insurance policies, most patients 
were previously administered oral therapies, such as vitamin E and 
pentoxifylline and/or other therapies, such as topical verapamil, 
without success.
Data on enrolled patients were recorded into a de-identified 
database. Protected health information about the patients was not 
recorded into the database in agreement with safe harbour of data 
collection. Furthermore, only researchers with proper training were 
permitted to investigate patient records. Patients' charts were re-
viewed to register date of birth, duration of Peyronie's Disease and 
any history of penile trauma during sexual activity, as well as other 
relevant clinical information that could impact the administration 
of CCHi, such as use of anticoagulants. At the baseline visit when 
CCHi treatment was discussed, the patient's penile curvature was 
measured via a patient-provided photograph or after prostaglandin 
injection in clinic. The baseline visit is defined as the visit of the first 
CCHi treatment. Thus, baseline data represent the situation just 
prior to the first injection.
2.2 | Treatment protocol and data collection
Inclusion criteria for the study were men with a dorsal, dorsolateral 
or lateral penile curvatures between 30 and 90 degrees, who were 
not anticoagulated with medication other than aspirin, and for whom 
insurance coverage for CCHi could be confirmed. Exclusion criteria 
included men with plaques and curvature less than 30 degrees, men 
on active anticoagulation, and men with dorsal, dorsolateral or lat-
eral penile curvatures between 30 and 90 degrees for whom insur-
ance authorisation could not be obtained.
The CCHi protocol used in this study consisted of treatment 
with 1–4 cycles of CCHi, as described in the package insert. Each 
CCHi cycle involved two injections (0.58 mg) separated by 48–72 hr. 
Cycles were separated by at least 6 weeks. After a minimum of 48 hr 
after the second injection of the series, a penile modelling session 
was scheduled. Patients were instructed how to perform the mod-
elling at home and provided the company instructions on specific 
technique including stretching and manual modelling.
At scheduled appointments for injections, patients were asked 
to fill out the “bother domain” of the PDQ along with a consent form 
for treatment, prior to injection treatment. Changes in their penile 
curvature were categorised as “worse”, “no change”, “little decrease”, 
“decrease”, “significant decrease”. Patient charts were re-examined 
in October 2019 to record if any patient had surgery after CCHi 
treatment.
2.3 | Statistics
Statistical analyses were performed with the use of computing en-
vironment	R	(http://www.r-proje	ct.rg/,	Vienna,	Austria).	A	one-way	
repeated	measure	analysis	of	variance	(ANOVA)	was	conducted	to	
evaluate the null hypothesis that there is no change in patients' PDQ 
scores following injections. Pairwise comparisons of PDQ scores at 
baseline and after each cycle were performed using paired samples 
t-test. To account for multiple comparisons, the Bonferroni correc-
tion was applied setting the significance level to 0.05/3 = 0.017.
3  | RESULTS
A	total	of	34	patients	were	enrolled	 in	 the	 study	between	January	
2016 and August 2018. Due to incomplete baseline values, seven pa-
tients were excluded from analysis. Baseline and clinical character-
istics of the 27 patients who completed the treatment are shown in 
Table 1. Four of these patients had a history of penile trauma while 
the aetiology of Peyronie's Disease in the remaining patients was un-
known. Five patients completed two CCHi cycles, four patients had 
three CCHi cycles and 18 patients had four cycles of CCHi (Figure 1). 
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Median follow-up time was 6 months (range 2–12) defined as the last 
documented visit in the clinic after the 1st cycle of CCHi treatment. 
However, patient charts were reviewed up to 46 months after the 1st 
cycle of CCHi to record if any patient had surgery after CCHi. Apart 
from mild bruising after injections, complications included one patient 
who reported increased plaque size but no increase in curvature, three 
patients with swelling and ecchymosis and one patient with moderate 
bruising and tenderness. No tunical ruptures were reported.
The mean baseline PDQ bother domain scores was 11.1 (2.6) 
(Table	 2).	 The	 result	 of	 the	 ANOVA	 indicated	 statistically	 signifi-
cant effect of injections (p < .001). Follow-up pairwise comparisons 
using paired samples t-test indicated statistically significant differ-
ences between the PDQ scores at baseline and 6 weeks after the 1st 
cycle (p = .013), between baseline and 6 weeks after the 2nd cycle 
(p = .009) and between PDQ scores at baseline and PDQ scores at 
6 weeks after the 3rd cycle (p < .001), respectively (Table 2, Figures 1 
and 2). In addition, 6 weeks after the 1st cycle all patients answered 
“yes” to PDQ question 3 (“Does your Peyronie's Disease make hav-
ing vaginal intercourse difficult or impossible”?), 6 weeks after the 
2nd cycle 15/18 answered “yes” and 6 weeks after the 3rd cycle 
14/17 answered “yes” (Table 2). After 2–4 cycles of CCHi, patients 
reported changes in penile curvature as “Worse” (0), “No Change” 
(2), “Little decrease” (10), “Decrease” (10) and “Significant decrease” 
(4). The two patients who reported “No Change” in penile curva-
ture after CCHi treatment proceeded with surgery. One patient had 
plaque incision and collagen fleece grafting with good results, but 
reported worsening of erectile dysfunction after the surgery. The 
other patient had plication and an inflatable penile prosthesis im-
plantation with good results. Finally, a patient reporting “Decrease” 
in curvature after CCHi treatment had a plication and afterwards 
complained of penile shortening. No unusual difficulties were expe-
rienced with any of the surgeries after CCHi treatment.
TA B L E  1   Clinical characteristics of patients treated with 
Collagenase Clostridium Histiolyticum injections
Age (years)
Mean ± SD 60 ± 9
Median (range) 62 (38–74)
Duration of Peyronie's disease (months)
Mean ± SD 26 (28)
Median (range) 14 (4–108)
History of penile trauma
n (%) 4 (15)
Pre-treatment curvature degree
Mean ± SD 56 ± 20
Median (range) 45 (30–90)
30–60° n (%) 19 (70)
61–90° n (%) 8 (30)
Pre-treatment curvature direction
Dorsal n (%) 22 (82)
Dorsolateral n (%) 2 (7)
Lateral n (%) 3 (11)
F I G U R E  1   Boxplot of PDQ scores at baseline and 6 weeks after the 1st, 2nd and 3rd CCHi cycle
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4  | DISCUSSION
This study demonstrated that CCHi treatment in a real-life environ-
ment resulted in a statistically significant decrease in PDQ bother 
scores 6 weeks after the 1st cycle, the 2nd cycle and the 3rd cycle 
when compared to baseline scores. Further, mean PDQ bother 
scores after completed CCHi treatment were below 9, which has 
been suggested as a cut-off for distinguishing clinically significant 
bother. When asked how their penile curvature had changed almost 
all patients reported a decrease in curvature, no patients reported 
worsening, and only two patients reported no change. However, 
14 of 17 patients answered “yes” to the PDQ question 3 (“Does 
your Peyronie's Disease make having vaginal intercourse difficult 
or impossible”?) 6 weeks after the 3rd cycle; whereas at baseline, 
all patients answered “yes” (n = 27). In addition, three patients had 
Peyronie's Disease surgery after CCHi treatment. These results 
are somewhat conflicting indicating overall positive effect of CCHi 
treatment on patients' penile curvature and bother, but little im-
provement in the ability to have vaginal intercourse.
Patients were offered a follow-up appointment after the 4th 
cycle if they were not satisfied; these appointments were either 
never scheduled by the patient or cancelled, explaining why data 
were not collected after the final series of injections. In addition, 
some patients were satisfied with the results during the treatment 
course and cancelled remaining cycles while others did not return 
for treatment without giving an explanation. No patient cancelled 
treatment due to adverse events.
Post-approval studies investigating the efficacy of CCHi treat-
ment have demonstrated similar results to the ones presented 
in this study regarding PDQ bother domain scores. In 189 men, 
Goldstein et al. (2017) reported a reduction in PDQ bother domain 
score of 2.4 points (6.3 at baseline to 3.9 after treatment) and pa-
tients experienced a mean 36.3% curvature reduction after four cy-
cles using the IMPRESS protocol. Yafi et al. (2018) demonstrated in 
18 patients that PDQ bother domain score decreased by 7 points 
(9.9 at baseline to 3.9 after treatment) and a curvature reduction 
of 34.4% with CCHi treatment using the IMPRESS protocol. Both 
studies concluded that CCHi is a safe and viable non-surgical option 
for treatment of Peyronie's Disease. The IMPRESS trials originally 
demonstrated a statistically significant improvement (p = .0037) 
in PDQ bother domain score after CCHi treatment (from 7.5 at 
baseline to 4.6 after treatment) (Gelbard, Goldstein, et al., 2013). 
These studies and the majority of other CCHi studies mainly focus 
on penile curvature reduction and frequently demonstrate positive 
results in this regard. However, objective and subjective measures 
in patients with Peyronie's Disease do not always align (Tsambarlis 
& Levine, 2019). Patient expectations and satisfaction as subjec-
tive parameters will not necessarily be reflected by objective pa-
rameters highlighting the important role of PROs in evaluation of 
Peyronie's Disease.
Few studies specifically investigate PROs such as patient' and 
partner satisfaction with CCHi treatmentZiegelmann et al. (2016) 
investigated 69 patients undergoing CCHi treatment with 31 com-
pleting all four cycles. The study focused on PROs as well as penile 
curvature improvement. The penile curvature was measured in 27 of 
the patients who completed all four cycles and 20 of those men ex-
perienced a curvature improvement of 20% or more. Furthermore, 
8 out of the 27 patients reported that the treatment restored their 
TA B L E  2   Treatment outcomes of patients treated with Collagenase Clostridium Histiolyticum injections
Baseline
6 week after 1st 
cycle
6 week after 2nd 
cycle





n 27 26 18 17 –
Mean ± SD 11.1 ± 2.6 9.9 ± 3.3 8.2 ± 4.0 6.5 ± 3.6
Median (range) 11 (7–16) 10.5 (3–14) 8.5 (2–15) 6.5 (1–12)
PDQ question 3b 
n 27 26 18 17 –
No n (%) 0 (0) 0 (0) 3 (17) 3 (18)
Yes n (%) 27 (100) 26 (100) 15 (83) 14 (82)
Curvature changec 
n – 5 3 18 26
Worse n (%) 0 (0) 0 (0) 0 (0) 0 (0)
No change n (%) 0 (0) 0 (0) 2 (11) 2 (8)
Little decrease n (%) 3 (60) 1 (33) 6 (33) 10 (38)
Decrease n (%) 2 (40) 1 (33) 7 (39) 10 (38)
Significant decrease n (%) 0 (0) 1 (33) 3 (17) 4 (15)
aDifferences between PDQ scores at baseline and PDQ scores at 6 weeks after the 1st, 2nd and 3rd cycles all statistically significant. 
bPDQ question 3: “Does your Peyronie's Disease make having vaginal intercourse difficult or impossible”? 
cReported for patients who completed respectively 1, 2, 3 and 1–4 Collagenase Clostridium Histiolyticum injections. 
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ability to have penetrative intercourse. In comparison, we found that 
only 3/17 were not bothered by their Peyronie's Disease when hav-
ing vaginal intercourse. Anaissie, Yafi, Traore, Sikka, and Hellstrom 
(2017) investigated patient and partner satisfaction after CCHi 
treatment for Peyronie's Disease. Using a self-designed satisfaction 
questionnaire, 16/24 patients reported overall satisfaction with the 
treatment and 17/24 female sexual partners were satisfied with the 
treatment. They found an overall post-treatment mean curvature re-
duction of 16 degrees (SD 10.7). Importantly, satisfaction was asso-
ciated with the ability to have sexual intercourse and not curvature 
reduction.
In general, a penile curvature of <30 degrees is believed not 
to cause partner discomfort and wont inhibit penetrative inter-
course (Ralph et al., 2010). However, few CCHi studies report a 
final mean penile curvature of <30 degrees, while patients might be 
satisfied and less bothered by the curvature after CCHi treatment 
(Gelbard, Goldstein, et al., 2013; Russo et al., 2018; Tsambarlis & 
Levine, 2019). This suggests that patient satisfaction is tied to other 
factors than curvature reduction. Serefoglu et al. (2017) performed 
a post hoc analysis of the IMPRESS trials data and assessed 608 pa-
tients' PDQ scores. They demonstrated that pain during intercourse 
had the greatest impact on PDQ bother domain score (p < .0001). 
Pain was present in 61% of the men during vaginal intercourse and 
53.1% experienced pain when the penis was erect. The authors sug-
gested that pain treatment may be practically beneficial for patients 
with Peyronie's disease. Pain during intercourse might partly ex-
plain why the majority of patients in our study still reported vaginal 
intercourse as being difficult or impossible after CCHi treatment. 
On the contrary, it might be that softening of the plaque by CCHi, 
that is not measured by a reduction in curvature, is felt by the pa-
tient during intercourse and provides some pain relief. In combina-
tion with a CCHi induced reduction in penile curvature, this might 
explain the satisfaction experienced by Peyronie's disease patients 
treated with CCHi. However, it does not seem that CCHi treatment 
makes vaginal intercourse free from discomfort as 82% of patients 
still reported that vaginal intercourse was difficult or impossible 
after CCHi treatment. Thus, patients should be informed that al-
though they can expect bother relief and reduction in curvature, 
the treatment will likely not make vaginal intercourse completely 
free for discomfort.
The main limitation of our study is the relatively small sample 
size for a single institution and the lack of a control group. Sample 
size was restricted due to the limitations of commercial insurance 
coverage, which also indicated a more homogeneous sample in 
terms of socioeconomic status. To have CCHi treatment covered by 
insurance, patients had to be previously treated with oral therapies, 
such as vitamin E and pentoxifylline and/or other therapies, such as 
topical	Verapamil.	This	might	have	prolonged	the	history	of	the	dis-
ease and could potentially have an impact on results. However, our 
prospective non-randomised clinical study represents a real-world 
post-marketing setting focusing on PROs that are important to pa-
tients treated for Peyronie's disease. Further, a strength of the study 
is that patients were followed up to assess if they had surgery per-
formed after CCHi treatment.
F I G U R E  2   Single patient's PDQ scores (y-axis) at baseline and 6 weeks after the 1st, 2nd and 3rd CCHi cycle
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In conclusion, patients with Peyronie's disease treated with CCHi 
report statistically significant decreases in PDQ bother domain 
scores and most patients report a decrease in penile curvature after 
treatment. However, the majority of patients still report difficulty 
with vaginal intercourse after CCHi treatment.
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